session, and because it could also be used in conjunction with WBRT. 24 A randomized clinical trial sponsored by the National Cancer Institute (RTOG 95-08) enrolling patients with 1-3 brain metastases showed a survival advantage and improved local control for consolidative SRS in patients with a single brain metastasis as compared with WBRT alone. 1 Statistically significant improvements in functional autonomy at 6 months follow-up were documented in the cohort randomized to WBRT and SRS, no matter whether 1, 2, or 3 metastases were treated with consolidative SRS.
A clinical trial begun by the Japanese Radiation Oncology Study Group (JROSG 99-1) turned this management strategy on its head. Aoyama et al. 2 asked if the addition of WBRT to upfront SRS for patients with 1-4 brain metastases showed any benefit for survival or neurological function compared with SRS alone. No survival advantage was observed with the use of WBRT, and there was no difference in neurological outcomes after 1 year. Editorial commentaries and letters regarding this study highlighted divergent opinions among neurosurgeons, neurooncologists, and radiation oncologists about the appropriateness of deferring WBRT in patients with 1-4 brain metastases treated with SRS. 11, 14, 15, 18 The publication of these 2 important studies and the increasing interest in SRS for brain metastases as an initial, definitive treatment raises the question of whether practice patterns for patients with newly diagnosed brain metastases might be becoming divergent. No data-driven, universally accepted management standards for brain metastasis management exist today for patients with 1-4 metastases, and even less data exist for patients with ≥ 5 brain metastases managed with anything more than WBRT. Despite the absence of data, patients are seeking SRS alone, and physicians have started to provide SRS as an initial definitive therapy for patients with far more numerous brain metastases than is supported by published randomized, controlled clinical trials.
Because of the lack of guidance from clinical trials for the physicians who would be offering this novel treatment, we conducted a survey of radiosurgery practitioners to help determine what patient, physician, and equipmentrelated factors may be associated with offering SRS as the first management step for brain metastases. Furthermore, we assessed physician characteristics associated with recommending first-line SRS for ≥ 5 metastases.
Methods

Study Design
We conducted a cross-sectional survey of physicians attending the 8th Biennial Congress and Exhibition of the International Stereotactic Radiosurgery Society in San Francisco in June 2007. The Yale University Human Investigation Committee provided approval for the collection of data on this subject. A second survey using the same instrument (translated into Japanese) was conducted at the 18th Annual Meeting of the Japanese Society of Stereotactic Radiosurgery in Sendai in July 2009.
Survey Instrument
The survey instrument collected information on survey participant demographics, experience, and SRS equipment used and was distributed to all physician attendees at a single session in both meetings. The survey asked physicians to use a 5-point Likert-type scale to score 14 clinical factors that were believed to possibly be important in making a decision about offering SRS as an initial, definitive therapy to patients with multiple brain metastases (ranging from 1 = not important to 5 = very important).
Factors that physicians were asked to rank in the survey included patient age; sex; KPS score; social situation; the presence of metastases-related neurological symptoms; location, size, and radiographic characteristics of the brain metastases (cystic vs solid, nonhemorrhagic vs hemorrhagic); presence or absence of mass effect; histopathology of the brain metastases; status of the patients' systemic disease control; and the availability of additional useful chemotherapy for the malignancy undergoing treatment. Self-assessed physician workload was also to be scored. Respondents were also given an opportunity to write in any additional factors they might consider important. Lastly, physicians were asked to write in a number to answer the question: "In general, a reasonable number of brain metastases treatable by SRS alone would be, at most, ."
Statistical Analysis
Results for each survey item addressing factors affecting the use of SRS were condensed into a single dichotomous outcome variable of "influential" (4-5) versus "not influential" (1-3). The characteristics of physicians willing to recommend SRS alone for ≥ 5 metastases were then assessed using bivariate chi-square tests, as well as multivariate logistic regression analysis (outcome: recommending SRS for ≥ 5 metastases). Statistical analyses were performed using STATA version 10.0.
Results
In San Francisco, 95 completed surveys were collected, and in Sendai, 54 were collected. The results of the demographic portions of these 2 surveys are summarized in Table 1 . The response to the query about what would be a reasonable number of brain metastases to be treated with SRS alone ranged from 2-50 in San Francisco and 3-50 in Sendai. In San Francisco, the median number of metastases considered reasonable to treat with SRS alone was 5 and the mean was 6.7; in Sendai, the median was 10 and the mean was 11. In San Francisco, 55% of physicians considered treating ≥ 5 metastases with SRS alone reasonable, and 22% of physicians considered it reasonable to treat ≥ 10 metastases with SRS alone. In Sendai, 83% of the physicians surveyed believed that treating ≥ 5 metastases with SRS alone was reasonable, and 57% of physicians believed that treating ≥ 10 metastases with SRS alone was reasonable.
Bivariate analysis (Table 2) showed that private practitioners were significantly more likely than academic physicians to consider SRS alone an appropriate initial definitive therapy for ≥ 5 brain metastases (77% vs 44%, respectively, in San Francisco, p = 0.002; 88% vs 69%, respectively, in Sendai, p = 0.017). Neurosurgeons were significantly more likely to recommend SRS for patients with ≥ 5 metastases than radiation oncologists (69% vs 39%, respectively, in San Francisco, p = 0.003; 93% vs 54%, respectively, in Sendai, p = 0.004), and physicians who use a Gamma Knife to perform SRS were also significantly more likely to recommend SRS alone than LINAC users (72% vs 35%, respectively, in San Francisco, p = 0.002; 100% vs 68%, respectively, in Sendai, p = 0.005).
A multivariate analysis performed on data collected in San Francisco confirmed that neurosurgeons (p = 0.033) and Gamma Knife users (p = 0.002) were independently significantly more likely to treat ≥ 5 metastases with SRS alone, whereas the impact of private practice versus academic practice was no longer significant. The OR of recommending treating ≥ 5 metastases with SRS alone was 4.2 for Gamma Knife users versus LINAC users (p = 0.002). The OR of recommending SRS alone for patients with ≥ 5 metastases was 2.7 for neurosurgeons compared with radiation oncologists (p = 0.033).
Neurosurgeons participating in the Japanese survey were more likely to be in community practice, and this factor correlated strongly with the opinion that SRS alone for ≥ 5 metastases was reasonable. Because 100% of Gamma Knife users at the Japanese meeting indicated that they would treat ≥ 5 metastases, a multivariate analysis was unable to provide stable parameter estimates (Gamma Knife use predicted the treatment recommendation for ≥ 5 metastases perfectly).
From the survey in San Francisco (Table 3) , the most influential decision-making factors were KPS score (78%), presence/absence of mass effect (76%), and systemic disease control (63%). Less important were metastases-related neurological symptoms (56%) or unrelated neurological disease (51%), metastases location (55%), patient age (50%), size of the metastases (45%), tumor histopathology (40%), and availability of additional potentially effective chemotherapy (38%). Radiographic appearance (20%), social situation (21%), and physician workload (5%) were mostly believed to not be influential factors. Nobody considered patient sex to be an influential factor.
At the Sendai meeting (Table 3) , the most influential factors were the size of the metastases (78%), KPS score (70%), and metastasis location (68%). Although less influential, the presence or absence of neurological symptoms from the metastases (57%), mass effect (57%), other neurological disease (48%), systemic diseases control (44%), stability of the patient's social situation (40%), patient age (35%), and tumor histopathology (39%) were all considered more important than the availability of additional potentially effective chemotherapy (26%) or the radiographic appearance of the metastatic disease (25%). As in San Francisco, only a small percentage (6%) of the physicians considered their own workload a significant factor when advising patients about SRS alone for brain metastases, and again, no one considered patient sex an influential factor.
Discussion
The key finding of this study is the previously undocumented willingness of more than half of the surveyed physicians who are experienced in radiosurgical treatment of brain metastases to offer and recommend SRS alone to patients with numerous brain metastases. The range of number of metastases considered reasonable to treat with first-line SRS was essentially the same at both survey locations (2-50 and 3-50). While the median and the mean number of metastases considered reasonable to treat with SRS alone were significantly different between San Francisco (mean 6.7, median 5) and Sendai (mean 11, median 10), both medians and means fall outside the 1-4 range set by the randomized controlled clinical trial data supported by the literature. 2 Stated conversely, the majority (55%) of physicians were willing to offer SRS alone to patients with ≥ 5 brain metastases at the 2007 meeting in San Francisco, and the vast majority (83%) were willing at a 2009 meeting in Sendai.
Although a minority (22%) of the clinicians surveyed at the 2007 meeting in San Francisco believed treating > 10 metastases was reasonable, a majority (57%) of those surveyed in Sendai in 2009 believed that using SRS alone for > 10 metastases was reasonable. It should be clearly recognized that this survey's overall response rate is unknown and that there is no knowledge about whether respondents differed from nonrespondents with regard to professional characteristics or inclination to use SRS, and that the generalizability of any analysis must be regarded as limited.
Based on the current literature, clinicians who strive to practice evidence-based medicine might not consider referring a patient with > 4 brain metastases for a consultative opinion regarding definitive SRS. Historical practice would certainly deem this acceptable, and such a patient might be offered WBRT without a discussion of SRS alone as a possible therapeutic option.
Given that the treatment of brain metastases with SRS is a labor-intensive process that requires the meticulous identification of each metastasis to be treated and the development and subsequent delivery of individualized, highly customized treatment plans, the escalating threshold of the number of "oligo" metastases that may "reasonably" be considered for SRS alone by radiosurgery practitioners is a remarkable finding. The more metastases that are treated, the more work (and more time) is involved, but our study shows that only 5% of physicians in San Francisco and 6% in Sendai considered their workload important in making a recommendation for SRS alone.
Our study further shows that neurosurgeons are more willing than radiation oncologists both in San Francisco and in Sendai to declare this management practice reasonable. This likely reflects differences in professional training and experience. Neurosurgeons implement focal treatments for intracranial pathology for mass effect or diagnosis and rarely see the benefits of WBRT, but only deal with its focal failures. In comparison, for a radiation oncologist, the use of a regional treatment such as WBRT is common, easy to institute, can prevent the progression of subclinical disease into clinically evident metastases, and can help control larger metastases that receive a focal treatment such as resection or SRS.
1,2,5,16 For a patient with multiple metastases in which staged craniotomies and resection of multiple metastases are rarely employed, the noninvasive focal alternative of SRS can be an attractive alternative that continues to involve the neurosurgeon.
The equipment used for SRS was also identified to be a significant variable in assessing whether individual physicians would treat a patient with SRS. Gamma Knife users in both surveys were statistically much more likely than LINAC users to offer SRS to a patient with ≥ 5 brain metastases. Why might opinions vary with the technology used? Treatment recommendations are guided by individual experience. The Gamma Knife machine is solely dedicated to the treatment of intracranial lesions accompanied by its own dedicated staff and the several hours required to provide comprehensive radiosurgical treatment can be accomplished during regular working hours. However, because LINACs are commonly used for treating many patients daily with fractionated radiotherapy, single-fraction SRS may only be started when the full daily roster of patients receiving fractionated radiotherapy is completed. Radiosurgical treatment for patients with multiple brain metastases with such equipment might often extend into the evening hours, and perhaps could lead to a greater likelihood to decline to offer SRS to a patient with multiple brain metastases by a busy radiation oncologist, particularly because of the higher potential of requiring additional short-term salvage treatment if WBRT is not part of the management plan. The absence of Class I data supporting the use of SRS alone for patients with > 4 brain metastases for important outcomes such as neurocognitive function provides good justification for such a management practice.
The recently published Phase III study by Chang et al., 5 however, may change this justification. 10 This study showed that short-term neurocognitive outcomes for patients who were treated with SRS alone for 1-3 metastases was significantly better than those receiving SRS and WBRT. A survival advantage was also observed for deferring WBRT. Because this study's primary end point was not survival, this observation may be due to an imbalance of treatment arms and asymmetrical use of aggressive salvage treatment rather than a true treatment effect. In addition to the 2 randomized controlled trials that have been published on the use of SRS with or without WBRT for up to 4 brain metastases, a third trial, also randomizing patients with 1-3 brain metastases between SRS alone and SRS with WBRT, is underway under the aegis of the National Cancer Institute as an Intergroup study (NCCTG-N0574) and is powered to evaluate neurocognitive outcomes in the two arms. 20 Controversy is almost certain concerning whether this new study's (NCCTG-N0574) results may be extrapolated to patients with 4 or more brain metastases. In addition, appropriate studies still need to be conducted to determine what other factors may be critical in determining which patients may be appropriate for initial, definitive SRS. Important factors might include age, comorbidities, tumor site of origin, and histology, and a host of other variables.
13 Rational patient management recommendations ideally derive from high quality studies performed on patient populations that appropriately reflect disease stage, severity, comorbidities, and available therapeutic options, but recommendations for populations in general often differ significantly from recommendations for individual patients. Treatment individualization is a hallmark of modern oncological and medical practice.
It is far from certain that even well-designed oncological clinical trials and meta-analyses will affect patient management patterns if their results run counter to the perceived benefit of the treatment. University of Toronto investigators surveyed American oncologists about management recommendations for 5 hypothetical patients with breast cancer. 4 One scenario-offering systemic chemotherapy to postmenopausal women with early stage, estrogen receptor-negative, axillary node-negative breast cancer-was noted by the authors as counter to both large randomized controlled trials and a metaanalysis of available trial data, as neither evaluation had shown a survival benefit for the use of adjuvant chemotherapy in that setting. It took additional trials and a metaanalysis with 10-and 15-year follow-up to document a survival advantage for women up to 70 years of age with early stage, node-negative breast cancer who received adjuvant systemic chemotherapy in Phase III trials testing the value of that intervention. 6 Expert opinion preceded confirmatory trial data in this oncological situation, but it is unlikely that clinical trials will ever adequately resolve all management questions regarding patients with brain metastases because of 2 major issues: the heterogeneity of patients presenting with brain metastases, and the short expected lifespan for patients with metastatic cancer.
Stereotactic radiosurgery as a single, definitive treatment for brain metastases has been used with increasing frequency in North America, Europe, Asia, and around the world. 2, 3, 5, 8, 12, [21] [22] [23] [24] This approach defers the use of WBRT to a supplementary or salvage role. Stereotactic radiosurgery has been documented to provide excellent control for targeted lesions, and the focal nature of SRS permits retreatment if additional oligometastatic brain metastases are identified on surveillance images after SRS. Whole brain radiation therapy can be used for salvaging of patients who develop metastatic involvement of the leptomeninges or miliary parenchymal metastases. This management approach represents a paradigm shift for the management of brain metastases. Whole brain radiation therapy has been the standard of care for approximately 50 years because of its ease of application and palliative benefit for patients with symptomatic metastases. Whole brain radiation therapy has also been proven to delay or prevent the growth of clinically inapparent metastases. Stereotactic radiosurgery is not ubiquitous, however, and not all radiation oncologists or neurosurgeons may offer this treatment to patients with brain metastases because of a lack of specialized equipment or of appropriate training.
The decision to survey physician attendees of the 8th Biennial Congress and Exhibition of the International Stereotactic Radiosurgery Society in San Francisco was undertaken to assess the factors that physicians (quite familiar with SRS) consider as significant when evaluating patients referred for an opinion regarding brain metastasis management. In the absence of guidelines derived strictly from evidence-based medicine, it was believed that value might be provided by determining what types of practices are common and what might be deemed acceptable in light of a changing paradigm for management of brain metastases. The survey instrument asked specific questions about the physician and the nature of their practice and equipment, and deliberately posed very general questions about patient and tumor-specific factors to avoid portraying clinical scenarios that might influence responses. A follow-up survey was performed at the 18th Annual Meeting of the Japanese Society for Stereotactic Radiosurgery in 2009 to try to confirm and extend the survey findings.
There are numerous limitations to interpretation of the survey responses obtained. No data were collected to allow an assessment of response rate of the physicians surveyed at the 2 meetings. The 2 surveys were conducted more than a year apart at radiosurgery meetings on 2 different continents. The San Francisco meeting was an international meeting, with physician attendance from around the globe, and the Sendai meeting was a national society's meeting. The different practice environments that these respondents practice in will confound simple comparisons over time or across practice environments. No data were collected about physician reimbursement schemes (single payer vs private health insurance, and others) or how reimbursement might affect recommendations for first-line SRS for multiple brain metastases. No data were collected about what LINAC platform or platforms might be associated with a greater willingness to perform SRS on ≥ 5 metastases. Finally, this analysis focused on the respondents' reported treatment patterns, rather than assessing actual patient care. Future work should explore actual patterns of patient care, as well as outcomes associated with different management options.
Conclusions
Stereotactic radiosurgery as a definitive initial management strategy for ≥ 5 brain metastases was considered reasonable by the majority of physicians attending radiosurgery conferences in 2007 and 2009, and at the second conference, the majority of physicians were willing to offer radiosurgery to patients with ≥ 10 metastases. Neurosurgeons and Gamma Knife users were more likely to recommend SRS alone for such patients. No clear consen-sus exists for how many metastases are reasonable to treat with SRS alone or what factors should be used to assess candidate patients. Given the early neurocognitive results from Chang et al., 5 there appears to be an advantage to a focal philosophy and the use of SRS alone for multiple brain metastases should be standard in first-line discussions regarding management of multiple metastases, even for patients with 5 or more metastases.
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